Lee's Pharm and SillaJen Approved for China Immunotherapy Trial

Lee's Pharm received CFDA approval for a Phase III trial of Pexa-Vec in patients with advanced liver cancer. The study is part of the PHOCUS global trial that was started in 2015. Lee's Pharm owns China rights to the drug, and SillaJen, a Korean immunotherapy company, is the global developer. Pexa-Vec is an engineered vaccinia poxvirus designed to kill cancer cells and provoke a natural immune response. The CFDA held an advisory committee meeting earlier this year to discuss the Pexa-Vec trial, the first such meeting under a new CFDA initiative to improve transparency. More details.... Stock Symbols: (HK: 0950) (KOSDAQ: 215600) Share this with colleagues: // //